Interferon alpha-2a - Amarillo/Hayashibara

Drug Profile

Interferon alpha-2a - Amarillo/Hayashibara

Alternative Names: IFN-alpha lozenges; MOR 22; Natural human lymphoblastoid interferon-alpha; Veldona

Latest Information Update: 10 Aug 2015

Price : $50

At a glance

  • Originator Hayashibara
  • Developer Amarillo Biosciences; CytoPharm; Hayashibara; Mochida Pharmaceutical; NOBEL ILAC; Otsuka Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Human papillomavirus infections; Polycythaemia vera; Behcet's syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Myeloid leukaemia; Renal cell carcinoma
  • Phase II Influenza virus infections
  • Clinical Phase Unknown Thrombocytopenia
  • No development reported Behcet's syndrome; Solid tumours
  • Discontinued Chronic obstructive pulmonary disease; Fibromyalgia; HIV infections; Human papillomavirus infections; Liver cancer; Polycythaemia vera; Pulmonary fibrosis; Sjogren's syndrome; Skin disorders; Thrombocytosis

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 10 Aug 2015 Phase-II development for Influenza virus infections (Prevention) is ongoing in Australia
  • 10 Aug 2015 Phase-II development for Influenza virus infections (Treatment) is ongoing in Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top